FIRST TRACKS BIOTHERAPEUTICS INC (TRAX)

Health Care · Biotechnology · NASDAQ

A clinical-stage biotechnology company developing novel antibody therapies to treat autoimmune and inflammatory conditions.

View SEC filings Filings archive → Large price moves → Website Find companies like TRAX → Ask about TRAX →

What FIRST TRACKS BIOTHERAPEUTICS INC does

First Tracks Biotherapeutics is a clinical-stage biotechnology company focused on developing antibody therapies that modulate immune pathways for autoimmune and inflammatory diseases. Its pipeline includes candidates targeting celiac disease, eosinophilic esophagitis, and rheumatoid arthritis.

Themes: Autoimmune disease therapies, Inflammatory disease treatments, Antibody-based therapeutics

Fundamentals

Price$32.01 as of 2026-10-08 close
Market cap$1.1B as of 2026-08-07 (share count; price 2026-10-08)
P/En/a earnings data not available
Debt / equity0.00 as of 2026-09-02
Beta1.40 as of 2026-09-02
Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)

Ask why TRAX looks like this →

How FIRST TRACKS BIOTHERAPEUTICS INC looks technically

FIRST TRACKS BIOTHERAPEUTICS INC (TRAX): there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 37, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 2 trading days ago. Trading volume is running unusually high — about 2.0× its 30-day average, a sign of heightened interest.

Trend

Distance from the 200-day	not enough price history yet — needs 200 trading sessions	n/a
50-day moving average	its average price over the last 50 trading days — a short-term trend line — is $40.73	$40.73
200-day moving average	not enough price history yet — needs 200 trading sessions	n/a
Swing structure	each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next	lower highs and lower lows
Last swing turn	its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on	16 sessions
Wave structure	its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 42.24. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C.	possible downward five-wave sequence, in wave 3 (one of several readings)
Since the 50/200 cross	not enough price history yet — needs 200 trading sessions	n/a
Trend strength (14-day ADX)	there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend)	16.1

Momentum

14-day RSI	momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 37, neither overbought (above 70) nor oversold (below 30)	36.8
Position in its 14-day range	it is trading near the bottom of its 14-day range ($30.11 to $42.24) — its "stochastic" reading is 16 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions.	15.7
Since the MACD crossed zero	MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish)	44 sessions

Range

Since a 20-day breakout	it made a new 20-day low about 2 trading days ago	2 sessions
Since a 55-day breakout	it made a new 55-day low about 2 trading days ago	2 sessions
All-time high	its highest closing price on record is $49.91 (set on 2026-08-11)	$49.91
Given back of the 52-week move	not available for this company yet	n/a
Nearest price level	not enough price history yet — needs 252 trading sessions	n/a
All-time low	its lowest closing price on record is $14.79 (set on 2026-04-20)	$14.79
Above the all-time low	it is 116.4% above its all-time low	+116.4%

Volatility

Band width vs its own 6 months	day-to-day price swings are about average versus its own recent 6-month history	56th percentile
Typical daily range	in a typical session it travels about $2.79 between its high and its low — about 8.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was	$2.79
Bollinger bands (20-day, ±2σ)	most of its recent trading has stayed between about $30.27 and $41.58 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles	$30.27 – $35.92 – $41.58
Typical daily range (% of price)	its price moves about 8.7% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price	8.7%

Volume

Volume vs its 30-day average	trading volume is running unusually high — about 2.0× its 30-day average, a sign of heightened interest	2.02×

Analyst

Change in the average price target	analysts have cut their average price target by 2.5% since the prior reading	-2.5%
Change in the consensus rating	the analyst consensus rating has improved toward "buy" since the prior reading	0.02 toward buy

Candlestick patterns

Since a bullish engulfing	8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it	8 sessions ago

Price gaps

Gap at the open	it opened on 2026-10-08 8.9% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close	+8.9%
Gap filled	a 8.9% gap up opened on 2026-10-08 has been "filled" today — price traded back through the level the gap left behind, and it closed again during the very session that opened it	today

Price streaks

Closing streak	it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run	1 session up

Relative strength

vs market, 1 month	over the past 1 month this stock lagged the market by 24.5 percentage points (the stock lost 23.4% while the market gained 1.0%)	-24.5%
vs market, 3 months	over the past 3 months this stock beat the market by 50.3 percentage points (the stock gained 54.1% while the market gained 3.8%)	+50.3%
vs market, 6 months	not available for this company yet	n/a
vs market, 12 months	not available for this company yet	n/a

Signal agreement

Bullish technical signals	1 of the 6 technical signals we can compute for it is currently in a bullish state: near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast	1 of 6
Bearish technical signals	3 of the 6 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast	3 of 6

Trend (Ichimoku cloud)

Vs the Ichimoku cloud	trading 2.4% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 35.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross.	-2.4%

Volume-weighted price

Vs this year’s average price paid	the price is sitting right on the average price paid since 2026-04-20, so the typical buyer over that stretch is roughly break-even. That average is $32.12 — a volume-weighted average of daily closes over 110 sessions, not a true tick-by-tick VWAP.	-0.3%
Vs the average paid since it last reported	the price is 18% below the average price paid since it last reported on 2026-08-12 (its 10-Q), so the typical buyer over that stretch is under water. That average is $39.23 — a volume-weighted average of daily closes over 41 sessions, not a true tick-by-tick VWAP.	-18.4%

Wave structure

Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.

This labelling fails — stops being a possible reading at all — if it closes above $42.24.

This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.

On past moves of this shape the leg has usually ended somewhere between $22.04 and $29.75 — that is where it has tended to end if the count holds, not a forecast of where the price goes.

Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $42.24.

This reading has stood for 8 trading days, since 2026-09-29.

Read from daily closes as of 2026-10-08.

An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.

Screens: Unusually heavy trading volume · Broke down to a new 20-day low · trendless / choppy (low ADX) · Analyst price target recently CUT · Gapped up at the open (3%+) · Just filled a gap (5%+ closed in the last week) | Learn: adx · rsi · breakout · volume and relative volume

Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.

Ask about TRAX's technicals →

Analyst consensus

Consensus ratingStrong Buy (1.25 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
Mean price target$70.00 range $50.00 – $100.00; median $65.00

Analyst estimates, as of 2026-10-06. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.

Analyst EPS estimate for TRAX

Consensus EPS estimate-$0.8854 next reporting period, as of 2026-10-06
Estimate change, 30 days-$0.00489 from -$0.8806, on 2026-09-01, 35-day window
Readings revised upward14% of 7 comparable readings

The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.

Ask how TRAX's estimates have moved →

Key risks (from latest filing)

["Dependence on successful development and regulatory approval of clinical candidates.","Need for additional financing to fund operations and potential material adverse effects if capital is unavailable.","Intense competition in the autoimmune and inflammatory disease therapeutic market."]

See TRAX's biggest risks from its latest 10-Q →

Insider activity (SEC Form 4)

0 open-market purchases and 1 open-market sale by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.

Last 90 days · read to 2026-10-040 buys · 1 sell ($2M) — 1 selling insider
Last 180 days · read to 2026-10-040 buys · 2 sells ($67M) — 2 selling insiders

Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)

Most recent open-market transaction: 2026-09-02. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.

View full insider trading history → View SEC Form 3/4/5 filings

Ask about TRAX's insider activity →

Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.

Institutional ownership (13F)

3 institutional 13F filers reported holding TRAX as of 2026-06-30 (quarter-end position, filed within 45 days).

Distinct 13F filers 3
Reported shares held 4,355,248
Reported value $87,627,601

Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.

Ask about TRAX's institutional holders → See what each manager we track holds →

Short interest (FINRA)

TRAX had 4,500,079 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).

TRAX had 12.6% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.5 days to cover at the same settlement.

Reported short interest (shares) 4,500,079
Short interest (% of shares outstanding) 12.6%
Prior settlement (shares) 4,030,463
Reported change 11.65%
Days to cover (reported) 7.5

Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.

Ask about TRAX's short interest →

Competitors & peers

AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.

Not quite? Describe exactly what you want →

Compare TRAX vs…

Frequently asked questions

What does FIRST TRACKS BIOTHERAPEUTICS INC (TRAX) do?

What sector is FIRST TRACKS BIOTHERAPEUTICS INC (TRAX) in?

FIRST TRACKS BIOTHERAPEUTICS INC (TRAX) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.

Who are FIRST TRACKS BIOTHERAPEUTICS INC's (TRAX) competitors?

Notable peers of FIRST TRACKS BIOTHERAPEUTICS INC (TRAX) include AnaptysBio, Amgen, Regeneron, AbbVie and Bristol Myers Squibb. This peer set is informational only — not financial advice.

Is FIRST TRACKS BIOTHERAPEUTICS INC (TRAX) overbought or oversold right now?

FIRST TRACKS BIOTHERAPEUTICS INC (TRAX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 37, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.

Where does stocks-llm's data on TRAX come from?

Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.

Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-10-08.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.